IJMS | Free Full-Text | Activity-Based Protein Profiling Reveals Potential Dasatinib Targets in Gastric Cancer | HTML
The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants | Cancer Research
The tyrosine kinase inhibitor dasatinib reduces the growth of intracellular Mycobacterium tuberculosis despite impairing T‐cell function - Wehrstedt - 2018 - European Journal of Immunology - Wiley Online Library
The most sensitive (IC50 < 1 nmol/L) cytosolic and membrane targets of... | Download Scientific Diagram
Targeting the kinome: bosutinib versus dasatinib. Emphasizing the... | Download Scientific Diagram
Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies in: Endocrine-Related Cancer Volume 21 Issue 3 (2014)
New drugs in the treatment of chronic myeloid leukaemia
A schematic model for the anti-cancer function of Dasatinib and... | Download Scientific Diagram
Mechanism of Action | Multikinase Inhibitors
Sprycel 70mg Tablets - Rosheta
Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors - ScienceDirect
Dasatinib-70 - Healeasy Services
Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia. - Abstract - Europe PMC
CML therapy : post-Gleevec® era - ppt download
Mode of action of imatinib. The phosphorylation of a substrate is shown... | Download Scientific Diagram
Tyrosine Kinase Inhibitors in Leukemia and Cardiovascular Events | Arteriosclerosis, Thrombosis, and Vascular Biology
IJMS | Free Full-Text | Philadelphia Chromosome-Positive Leukemia in the Lymphoid Lineage—Similarities and Differences with the Myeloid Lineage and Specific Vulnerabilities | HTML
BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis? - Abstract - Europe PMC
TYROSINE KINASE INHIBITORS
Dasatinib - Tyrosine Kinase Inhibitor for Chronic Myeloid Leukaemia (CML) - Clinical Trials Arena
Tyrosine Kinase Inhibitors in Leukemia and Cardiovascular Events | Arteriosclerosis, Thrombosis, and Vascular Biology
Mechanisms, Monitoring, and Management of Tyrosine Kinase Inhibitors A | OTT
Bcr-Abl tyrosine-kinase inhibitor - Wikipedia
